US biotech firm Revance Therapeutics (Nasdaq: RVNC) saw its
shares leap 19.5% to $24.91 by close of trading Tuesday, after it
announced a licensing deal for its Botox rival (RT002 and some
positive new clinical data for the investigational compound.

Revance has entered into a license agreement with a wholly-owned
subsidiary of Fosun Pharma (HK: 02196) with the exclusive rights
to develop and commercialize Revance’s proprietary
daxibotulinumtoxinA…

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

• All the news that moves the needle in pharma and biotech.
• Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
• Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

• Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
• Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
• Daily roundup of key events in pharma and biotech.
• Monthly in-depth briefings on Boardroom appointments and M&A news.
• Choose from a cost-effective annual package or a flexible monthly subscription.